Japanese cedar/cypress pollinosis
Conditions
Interventions
In February 1st, 2010, patients begin to receive mometasone self-administered two sprays in each nostril once daily in the morning (total dose of MF 200 ug). This treatment is continued until the end
Sponsors
Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (a) at least two year history of JCCP, (b) sensitization to Japanese cedar pollen assessed by skin prick test, (c) ability to fill in the diary cards accurately.
Exclusion criteria
Exclusion criteria: (a) concomitant sinonasal disease affecting the outcomes of this trial (e.g. nasal polyps, rhinosinusitis, nasal septum deviation); (b) concomitant treatment-requiring allergic rhinitis caused by allergens other than Japanese cedar/cypress pollen; (c) rhinitis medicamentosa and non-infectious, non-allergic rhinitis; (d) cedar pollen-specific immunotherapy; (e) sinonasal surgery including laser vaporization of inferior turbinates within 1 year; (f) medication with anti-allergic drugs including antihistamines, chromons, glucocorticoids and decongentants within 2 weeks; (g) hypersensitivity to MFNS; (h) systemic infection including mycosis; (i) pregnancy and breastfeeding.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Comparison of total nasal symptom score (TNSS) between active and placebo group | — |
Countries
Japan
Outcome results
None listed